TACSTD2 and prostate neoplasm: The 2EF mAb was demonstrated to bind Trop-2 at cell-cell junctions in MCF-7 breast cancer cells, and in deeply-seated sites in DU-145 prostate tumors, that were inaccessible to benchmark anti-Trop-2 antibodies.